4-[5-氯甲基-3-苯基异恶唑-4-基]苯磺酰胺 | 181696-34-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-[5-氯甲基-3-苯基异恶唑-4-基]苯磺酰胺
• 英文名称: 4-[5-chloromethyl-3-phenylisoxazol-4-yl]benzenesulfonamide
• 英文别名: 4-[5-(Chloromethyl)-3-phenyl-1,2-oxazol-4-yl]benzenesulfonamide
• CAS: 181696-34-4
• 化学式: C₁₆H₁₃ClN₂O₃S
• 分子量: 348.81
• InChiKey: JCVNIGQCRRPLCI-UHFFFAOYSA-N

物化性质

• 沸点：
  547.4±60.0 °C(Predicted)
• 密度：
  1.380±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  94.6
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-[5-氯甲基-3-苯基异恶唑-4-基]苯磺酰胺 在 甲酸 、 三乙胺 、 水 、 sodium hydroxide 作用下， 以 乙腈 为溶剂， 反应 8.0h， 以69%的产率得到1-羟基伐地考昔
  参考文献：
  名称：

  [EN] COXIB-DERIVED CONJUGATE COMPOUNDS AND METHODS OF USE THEREOF
  [FR] COMPOSÉS CONJUGUÉS DÉRIVÉS DE COXIB ET MÉTHODES D'UTILISATION DE CEUX-CI

  摘要：

  本文披露了从Celecoxib和Valdecoxib衍生的化合物及其使用方法。这些化合物可用于识别和定位导致患者疼痛感的病理和/或炎症部位；用于识别原发、继发、良性或恶性肿瘤的部位；以及用于诊断感染或确认或排除疑似感染。这些化合物含有放射性物质，可用于成像。这些化合物会聚集在环氧合酶表达增加的部位，如COX-2表达增加的区域，从而揭示了与疼痛和炎症相关的前列腺素产生增加的部位，并与肿瘤存在和/或位置相关。识别COX表达增加的区域还可用于筛查感染，评估类风湿关节炎的诊断和治疗的疗效，以及评估是否需要使用阿片类药物治疗。

  公开号：

  WO2022076741A1
• 作为产物：
  描述：

  生成 4-[5-氯甲基-3-苯基异恶唑-4-基]苯磺酰胺
  参考文献：
  名称：

  Substituted isoxazoles for the treatment of inflammation

  摘要：

  描述了一类取代的异氧氮杂环化合物，用于治疗炎症和与炎症相关的疾病。特别感兴趣的化合物由公式（III）定义，其中R7从羟基，低烷基，羧基，卤素，低羧基烷基，低烷氧羰基烷基，低烷氧基烷基，低羧氧基烷氧基，低卤代烷基，低卤代烷基磺酰氧基，低羟基烷基，低芳基（羟基烷基），低羧基芳氧基烷基，低烷氧羰基芳氧基烷基，低环烷基，低环烷基烷基和低芳基烷基中选择；R8是一个或多个基团，独立地从氢化物，低烷基亚砜基，低烷基，氰基，羧基，低烷氧羰基，低卤代烷基，羟基，低羟基烷基，低卤代氧基，氨基，低烷基氨基，低芳基氨基，低氨基烷基，硝基，卤素，低烷氧基，氨基磺酰基和低烷硫基中独立选择；或其药学上可接受的盐。

  公开号：

  EP1223167A3

文献信息

• Use of carotenoids and/or carotenoid derivatives/analogs for reduction/inhibition of certain negative effects of COX inhibitors
  申请人：Lockwood Samuel F.

  公开号：US20080293679A1

  公开（公告）日：2008-11-27

  Administering carotenoids, and in particular xanthophyll carotenoids, or analogs or derivatives of astaxanthin, lutein, zeaxanthin, lycoxanthin, lycophyll, or lycopene to a subject undergoing treatment with COX-2 inhibitor drugs may reduce at least a portion of the adverse side effects associated with administration of COX-2 selective inhibitor drugs. The carotenoids, or analogs or derivatives thereof may be administered to a subject prior to, at the same time as, or after the commencement of COX-2 selective inhibitor drug therapy. The carotenoids, or analogs or derivatives thereof may be administered to a subject concurrently with COX-2 selective inhibitor drugs therapy. The carotenoids, or analogs or derivatives thereof may be incorporated into pharmaceutical preparation in combination with the COX-2 selective inhibitor drug or may be administered separately. Administration of the analogs or derivatives described herein may reduce peroxidation of LDL and other lipids in the serum and plasma cell membranes of subjects undergoing COX-2 selective inhibitor drug therapy. Administration of the analogs or derivatives described herein may reduce the incidence of deleterious clinical cardiovascular events undergoing COX-2 selective inhibitor drug therapy.

  向正在接受COX-2抑制剂治疗的受试者施用类胡萝卜素，特别是黄质类胡萝卜素，或者是天然类胡萝卜素的类似物或衍生物，如虾青素、叶黄素、玉米黄质、莱科黄素、莱科菲或番茄红素，可能会减少与使用COX-2选择性抑制剂药物相关的不良副作用的至少一部分。这些类胡萝卜素，或者是其类似物或衍生物，可以在受试者开始接受COX-2选择性抑制剂药物治疗之前、同时或之后进行施用。这些类胡萝卜素，或者是其类似物或衍生物，可以与COX-2选择性抑制剂药物治疗同时进行施用。这些类胡萝卜素，或者是其类似物或衍生物，可以与COX-2选择性抑制剂药物组合在一起制成药物制剂，也可以单独施用。施用本文所述的类似物或衍生物可能会减少正在接受COX-2选择性抑制剂药物治疗的受试者血清和血浆细胞膜中低密度脂蛋白和其他脂质的过氧化。施用本文所述的类似物或衍生物可能会减少正在接受COX-2选择性抑制剂药物治疗的受试者发生有害的临床心血管事件的几率。
• Substituted isoxazoles for the treatment of inflammation
  申请人：G.D. Searle & Co.

  公开号：EP1223167A3

  公开（公告）日：2002-08-07

  A class of substituted isoxazolyl compounds is described for use in treating inflammation and inflammation-related disorders. Compounds of particular interest are defined by Formula (III) wherein R7 is selected from hydroxyl, lower alkyl, carboxyl, halo, lower carboxylalkyl, lower alkoxycarbonylalkyl, lower alkoxyalkyl, lower carboxyalkoxyalkyl, lower haloalkyl, lower haloalkylsulfonyloxy, lower hydroxyalkyl, lower aryl (hydroxylalkyl), lower carboxyaryloxyalkyl, lower alkoxycarbonylaryloxyalkyl, lower cycloalkyl, lower cycloalkylalkyl, and lower aralkyl; and wherein R8 is one or more radicals independently selected from hydrido, lower alkylsulfinyl, lower alkyl, cyano, carboxyl, lower alkoxycarbonyl, lower haloalkyl, hydroxyl, lower hydroxyalkyl, lower haloalkoxy, amino, lower alkylamino, lower arylamino, lower aminoalkyl, nitro, halo, lower alkoxy, aminosulfonyl, and lower alkylthio; or a pharmaceutically-acceptable salt thereof.

  描述了一类取代的异氧氮杂环化合物，用于治疗炎症和与炎症相关的疾病。特别感兴趣的化合物由公式（III）定义，其中R7从羟基，低烷基，羧基，卤素，低羧基烷基，低烷氧羰基烷基，低烷氧基烷基，低羧氧基烷氧基，低卤代烷基，低卤代烷基磺酰氧基，低羟基烷基，低芳基（羟基烷基），低羧基芳氧基烷基，低烷氧羰基芳氧基烷基，低环烷基，低环烷基烷基和低芳基烷基中选择；R8是一个或多个基团，独立地从氢化物，低烷基亚砜基，低烷基，氰基，羧基，低烷氧羰基，低卤代烷基，羟基，低羟基烷基，低卤代氧基，氨基，低烷基氨基，低芳基氨基，低氨基烷基，硝基，卤素，低烷氧基，氨基磺酰基和低烷硫基中独立选择；或其药学上可接受的盐。
• [EN] SUBSTITUTED ISOXAZOLES FOR THE TREATMENT OF INFLAMMATION<br/>[FR] ISOXAZOLES SUBSTITUES UTILISABLES DANS LE TRAITEMENT D'INFLAMMATIONS
  申请人：G.D. SEARLE & CO.

  公开号：WO1996025405A1

  公开（公告）日：1996-08-22

  (EN) A class of substituted isoxazolyl compounds is described for use in treating inflammation and inflammation-related disorders. Compounds of particular interest are defined by Formula (III) whrein R7 is selected from hydroxyl, lower alkyl, carboxyl, halo, lower carboxyalkyl, lower alkoxycarbonylalkyl, lower alkoxyalkyl, lower carboxyalkoxyalkyl, lower haloalkyl, lower haloalkylsulfonyloxy, lower hydroxylalkyl, lower aryl (hydroxylalkyl), lower carboxyaryloxyalkyl, lower alkoxycarbonylaryloxyalkyl, lower cycloalkyl, lower cycloalkylalkyl, and lower aralkyl; and wherein R8 is one or more radicals independently selected from hydrido, lower alkylsulfinyl, lower alkyl, cyano, carboxyl, lower alkoxycarbonyl, lower haloalkyl, hydroxyl, lower hydroxyalkyl, lower haloalkoxy, amino, lower alkylamino, lower arylamino, lower aminoalkyl, nitro, halo, lower alkoxy, aminosulfonyl, and lower alkylthio; or a pharmaceutically-acceptable salt thereof.(FR) Cette invention concerne une classe de composés d'isoxazolyle substitué pouvant être utilisés dans le traitement d'inflammations et de troubles liés à des inflammations. Les composés suscitant un intérêt particulier sont représentés par la formule (III), dans laquelle R7 est choisi parmi hydroxyle, alkyle inférieur, carboxyle, halo, carboxyalkyle inférieur, alcoxycarbonylalkyle inférieur, alcoxyalkyle inférieur, carboxyalcoxyalkyle inférieur, haloalkyle inférieur, haloalkylsulfonyloxy inférieur, hydroxylalkyle inférieur, aryle(hydroxylalkyle) inférieur, carboxyaryloxyalkyle inférieur, alcoxycarbonylaryloxyalkyle inférieur, cycloalkyle inférieur, cycloalkylalkyle inférieur et aralkyle inférieur; et R8 représente un ou plusieurs radicaux choisis indépendamment parmi hydrido, alkylsulfinyle inférieur, alkyle inférieur, cyano, carboxyle, alcoxycarbonyle inférieur, haloalkyle inférieur, hydroxyle, hydroxyalkyle inférieur, haloalcoxy inférieur, amino, alkylamino inférieur, arylamino inférieur, aminoalkyle inférieur, nitro, halo, alcoxy inférieur, aminosulfonyle et alkylthio inférieur. Cette invention concerne également les sels de ces composés acceptables sur le plan pharmaceutique.

  本发明涉及一类取代的异噁唑基化合物，用于治疗炎症和与炎症相关的疾病。特别感兴趣的化合物由公式（III）定义，其中R7选自羟基，较低的烷基，羧基，卤素，较低的羧基烷基，较低的烷氧羰基烷基，较低的烷氧基烷基，较低的羧氧基烷氧基烷基，较低的卤代烷基，较低的卤代烷基磺酰氧基，较低的羟基烷基，较低的芳基（羟基烷基），较低的羧基芳氧基烷基，较低的烷氧羰基芳氧基烷基，较低的环烷基，较低的环烷基烷基和较低的芳基烷基；R8是一个或多个基团，独立选择自氢，较低的烷基亚砜基，较低的烷基，氰基，羧基，较低的烷氧羰基，较低的卤代烷基，羟基，较低的羟基烷基，较低的卤代烷氧基，氨基，较低的烷基氨基，较低的芳基氨基，较低的氨基烷基，硝基，卤素，较低的烷氧基，氨基磺酰基和较低的烷硫基；或其药学上可接受的盐。
• Cyclooxygenase-2 selective inhibitors, compositions and methods of use
  申请人：Bandarage K. Ipul

  公开号：US20060194861A1

  公开（公告）日：2006-08-31

  The invention describes novel cyclooxygenase 2 (COX-2) selective inhibitors and novel compositions comprising at least one cyclooxygenase 2 (COX-2) selective inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one COX-2 selective inhibitor, optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor, and/or, optionally, at least one therapeutic agent. The novel cyclooxygenase 2 selective inhibitors of the invention can be optionally nitrosated and/or nitrosylated. The invention also provides methods for treating inflammation, pain and fever; for treating and/or improving the gastrointestinal properties of COX-2 selective inhibitors; for facilitating wound healing; for treating and/or preventing renal and/or respiratory toxicity; for treating and/or preventing other disorders resulting from elevated levels of cyclooxygenase-2; and for improving the cardiovascular profile of COX-2 selective inhibitors.

  该发明描述了新颖的环氧合酶2（COX-2）选择性抑制剂以及至少包含一种环氧合酶2（COX-2）选择性抑制剂的新型组合物，以及可选地至少包含一种捐赠、转移或释放一氧化氮的化合物，刺激内源性一氧化氮的合成，提高内源性的内皮衍生性松弛因子的水平或是一氧化氮合酶的底物，和/或至少一种治疗剂。该发明还提供了新型工具包，其中包括至少一种COX-2选择性抑制剂，可选地硝化和/或硝酰化，以及可选地至少一种一氧化氮供体和/或可选地至少一种治疗剂。该发明的新型环氧合酶2选择性抑制剂可以可选地硝化和/或硝酰化。该发明还提供了治疗炎症、疼痛和发热的方法；用于治疗和/或改善COX-2选择性抑制剂的胃肠道特性；促进伤口愈合的方法；用于治疗和/或预防肾脏和/或呼吸系统毒性的方法；用于治疗和/或预防由于环氧合酶2水平升高而导致的其他疾病的方法；以及用于改善COX-2选择性抑制剂的心血管特性的方法。
• CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE
  申请人：Bandarage Upul K.

  公开号：US20090005350A1

  公开（公告）日：2009-01-01

  The invention describes novel cyclooxygenase 2 (COX-2) selective inhibitors and novel compositions comprising at least one cyclooxygenase 2 (COX-2) selective inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one COX-2 selective inhibitor, optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor, and/or, optionally, at least one therapeutic agent. The novel cyclooxygenase 2 selective inhibitors of the invention can be optionally nitrosated and/or nitrosylated. The invention also provides methods for treating inflammation, pain and fever; for treating and/or improving the gastrointestinal properties of COX-2 selective inhibitors; for facilitating wound healing; for treating and/or preventing renal and/or respiratory toxicity; for treating and/or preventing other disorders resulting from elevated levels of cyclooxygenase-2; and for improving the cardiovascular profile of COX-2 selective inhibitors.

  本发明描述了新型环氧合酶2（COX-2）选择性抑制剂和包含至少一种环氧合酶2（COX-2）选择性抑制剂的新型组合物，以及可选择地至少包含一种捐赠、转移或释放一氧化氮、刺激内源性一氧化氮合成、提高内源性内皮源性舒张因子水平或是一氧化氮合酶底物的化合物和/或至少一种治疗剂的组合物。本发明还提供了包含至少一种COX-2选择性抑制剂，可选择性地硝化和/或硝酰化，以及可选择性地至少一种一氧化氮供体和/或至少一种治疗剂的新型试剂盒。本发明中的新型环氧合酶2选择性抑制剂可以选择性地硝化和/或硝酰化。本发明还提供了治疗炎症、疼痛和发热的方法；用于治疗和/或改善COX-2选择性抑制剂的胃肠道性质；用于促进伤口愈合；用于治疗和/或预防肾脏和/或呼吸系统毒性；用于治疗和/或预防由于环氧合酶-2水平升高而导致的其他疾病；以及用于改善COX-2选择性抑制剂的心血管特征的方法。